DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
67.40
-1.03 (-1.51%)
At close: Jan 9, 2026, 4:00 PM EST
67.55
+0.15 (0.22%)
After-hours: Jan 9, 2026, 7:24 PM EST
DexCom Revenue
DexCom had revenue of $1.21B in the quarter ending September 30, 2025, with 21.64% growth. This brings the company's revenue in the last twelve months to $4.52B, up 14.21% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.52B
Revenue Growth
+14.21%
P/S Ratio
5.84
Revenue / Employee
$438,437
Employees
10,300
Market Cap
26.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 83.70M | 109.70% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DXCM News
- 2 days ago - Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - Business Wire
- 16 days ago - HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 18 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit – DXCM - GlobeNewsWire
- 22 days ago - Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 24 days ago - 4 Reasons Why DexCom Could Be A Good Buy For 2026 - Seeking Alpha
- 4 weeks ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM - PRNewsWire
- 4 weeks ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha
- 5 weeks ago - Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights Before Upcoming Deadlines - GlobeNewsWire